BioMarin Pharma (BMRN) Tops Q2 EPS by 8c, Affirms FY Revenue Guidance, Lowers R&D Expense Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Wall St subdued in choppy trade after big bank earnings, chips slide
- Oil prices ease as US-Russia diesel deal hopes offset Middle East attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
| BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) | Delayed: 55.33 -0.06 (0.11%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $55.39 | 52 Week High | $108.96 | |||
| Open | $55.30 | 52 Week Low | $62.12 | |||
| Day High | $55.66 | P/E | N/A | |||
| Day Low | $54.59 | EPS | $-1.27 | |||
| Volume | 377,345 | |||||
